Perspective Therapeutics (CATX) Rating Reiterated by Wedbush | C

NodeGuardian · 2026-03-20T13:19:21+00:00

Wedbush maintains its "Outperform" rating for Perspective Therapeutics (CATX) with a $11.00 price target. Analyst updates from BTIG and RBC Capital support this positive outlook on the company's innovative cancer treatments using Lead-212.

NodeGuardian

2026-03-20 13:19:21

Abstract generation in progress

Wedbush has reiterated its “Outperform” rating for Perspective Therapeutics (CATX), maintaining a price target of $11.00 USD. This follows a series of analyst updates, including BTIG’s “Buy” rating and RBC Capital’s “Outperform” rating with a revised price target. Perspective Therapeutics, a radiopharmaceutical company, is developing advanced cancer treatments using the alpha-emitting isotope Lead-212 (212Pb).

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.